Goldman Sachs Maintains Buy on Abbott Laboratories (ABT) Stock

Goldman Sachs analyst David Roman maintained a "Buy" rating on Abbott Laboratories (NYSE:ABT) on May 27, reducing the price objective to $113.00 from $121.00. The stock is considered one of the best blue chip stocks under $100 to buy now.

Rating Change

• Previous Rating: Buy with a price target of $121.00.
• Current Rating: Buy with a price target of $113.00.

Analyst Rationale

The analyst believes the price target reduction does not reflect a change in the company's fundamental outlook, but rather market adjustments. The positive rating is supported by:

• Improvements in fundamentals.
• Attractive valuation at current levels (under $100).
• Abbott's position as a leading healthcare blue chip.

Context

No other analyst recommendations were specifically mentioned, but the stock is highlighted among top blue chips under $100. The stock has shown stable performance amid current market conditions.

What to Make of It

Goldman Sachs remains positive on Abbott Laboratories, emphasizing strong fundamentals. Investors may view the lowered price target as a buying opportunity at lower levels.